文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

EPHA基因变异与紫杉醇所致周围神经病变敏感性相关

Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
PubMed 文献 · Br J Clin Pharmacol · 2020-02-04

该研究对60例乳腺癌患者进行胚系DNA测序,将EPHA4/5/6/8遗传变异纳入已发表的整合紫杉醇暴露与累积治疗的PN预测模型,评估其与PN敏感性的关联。结果发现EPHA5 rs7349683与PN敏感性增加相关,错义变异总数与PN敏感性降低相关,但均未检测到与治疗中断的关联。

要点

  • EPHA5 rs7349683与紫杉醇所致PN敏感性增加相关。
  • 错义变异总数与PN敏感性降低相关。
  • rs7349683或错义变异总数均未显示与治疗中断相关。

核心结论

  • EPHA5 rs7349683是紫杉醇所致PN敏感性的潜在标志物,可能用于个体化治疗。

研究设计与样本

  • 对60例乳腺癌患者胚系DNA进行测序,将EPHA4、EPHA5、EPHA6和EPHA8遗传变异纳入已发表的整合紫杉醇暴露与累积治疗的PN预测模型,测试3种遗传模型。

主要发现

  • EPHA5 rs7349683(次要等位基因频率=0.32)与PN敏感性增加相关(β系数=0.39,95%CI 0.11-0.67,P=0.007)。
  • 未检测到错义变异总数或rs7349683与治疗中断的关联。

关键数值与推荐

  • 设定CIPN8最大可耐受阈值为30时,rs7349683纯合子患者的最佳紫杉醇暴露目标为11.6小时,短于杂合子(12.6小时)或野生型(13.6小时)患者。

临床怎么用

  • 在临床实践中,可考虑检测EPHA5 rs7349683及错义变异总数,结合治疗药物监测个体化调整紫杉醇暴露目标以降低PN风险。

局限性

  • 样本量较小(60例乳腺癌患者),未检测到与治疗中断的关联,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Chemotherapy-induced peripheral neuropathy (PN) is a treatment limiting toxicity of paclitaxel. We evaluated if EPHA genetic variation (EPHA4, EPHA5, EPHA6, and EPHA8) is associated with PN sensitivity by accounting for variability in systemic paclitaxel exposure (time above threshold). METHODS: Germline DNA from 60 patients with breast cancer was sequenced. PN was measured using the 8-item sensory subscale (CIPN8) of the patient-reported CIPN20. Associations for 3 genetic models were tested by incorporating genetics into previously published PN prediction models integrating measured paclitaxel exposure and cumulative treatment. Significant associations were then tested for association with PN-related treatment disruption. RESULTS: EPHA5 rs7349683 (minor allele frequency = 0.32) was associated with increased PN sensitivity (β-coefficient = 0.39, 95% confidence interval 0.11-0.67, p = 0.007). Setting a maximum tolerable threshold of CIPN8 = 30, optimal paclitaxel exposure target is shorter for rs7349683 homozygous (11.6 h) than heterozygous (12.6 h) or wild-type (13.6 h) patients. Total number of missense variants (median = 0, range 0-2) was associated with decreased PN sensitivity (β-coefficient: -0.42, 95% confidence interval -0.72 to -0.12, P = .006). No association with treatment disruption was detected for the total number of missense variants or rs7349683. CONCLUSION: Isolating toxicity sensitivity by accounting for exposure is a novel approach, and rs7349683 represents a promising marker for PN sensitivity that may be used to individualize paclitaxel treatment.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Marcath LA, Kidwell KM, Vangipuram K, et al. Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy. Br J Clin Pharmacol. 2020. PMID: 31823378. doi:10.1111/bcp.14192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。